Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 55.30
Day High 56.22
Open:55.72
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

AstraZeneca Partners with Actor and Author Tony Hale to Build Awareness of Eosinophilic Asthma and How Not All Asthma is the Same
- BusinessWire - Tue Aug 11, 6:30AM CDT
BusinessWire - CMTX
Tue Aug 11, 6:30AM CDT
AstraZeneca is partnering with Tony Hale, two-time Emmy-winning actor and author, to share his lifelong journey as an asthma sufferer, in an effort to help others understand the importance of learning what's driving their asthma.
Global Pandemic Creating Opportunities for Drug Companies to Earn Positive Market Attention
- PR Newswire - PRF - Thu Aug 6, 7:45AM CDT
PR Newswire - PRF - CMTX
Thu Aug 6, 7:45AM CDT
, /PRNewswire/ -- In the last 18 years, viral disease epidemics have across the globe. Today's pandemic is quickly adding to the number of deaths while seriously disrupting economies, businesses, and . In the middle of all the chaos are pharmaceutical companies that health experts and the public have turned to for hope. As the put it, "one lesson from this pandemic is on an innovative and robust pharmaceutical industry." In response, pharma leaders are stepping up to meet the diverse needs of their target markets, such as (NYSE: PFE) and (NYSE: LLY) developing new potential vaccines and treatments, and ,(NASDAQ: GILD), and (TSX: CRDL) (OTCQX:CRTPF) leveraging existing drugs to address the pandemic.
NeoTX to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
- GlobeNewswire - Mon Aug 3, 7:00AM CDT
GlobeNewswire - CMTX
Mon Aug 3, 7:00AM CDT
NeoTX Therapeutics, a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection (STR) platform to develop targeted cancer immunotherapies, today announced it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place August 4-5, 2020. Chief Executive Officer, Asher Nathan, will deliver a corporate update to potential investors and strategic partners, among other various relevant audiences. The presentation will cover recent and upcoming Company milestones, as well as detail clinical progress of the Company's lead candidate, naptumomab estafenatox ("Nap"), currently being evaluated in a Phase1b clinical trial for the treatment of advanced and metastatic solid tumors in combination with AstraZeneca's (NYSE: AZN) checkpoint inhibitor IMFINZI(R) (durvalumab).
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 53.12 +4.61% increase
on 07/13/20
Period Open:53.76
Price movement based on the high, low and last over the given period.
64.94 -14.43% decrease
on 07/20/20
+1.81 (+3.37%) increase
since 07/10/20
3-Month 50.81 +9.37% increase
on 05/27/20
Period Open:53.95
Price movement based on the high, low and last over the given period.
64.94 -14.43% decrease
on 07/20/20
+1.62 (+3.00%) increase
since 05/11/20
52-Week 36.15 +53.72% increase
on 03/16/20
Period Open:44.77
Price movement based on the high, low and last over the given period.
64.94 -14.43% decrease
on 07/20/20
+10.80 (+24.12%) increase
since 08/09/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies